The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

Richard Balanson says when one suffers a disease "you begin to accumulate friends" who have their own story with the same ...

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

Taryn Robertson, a professor at Randolph College, is currently fundraising and training to run a marathon for her father who ...

Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...

A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wearable subcutaneous infusion ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's ...

Traditional deep brain stimulation surgery can take up to 10 hours to complete, with the patient wide awake. This robotic ...

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...